

**Claim Amendments:**

1. (Previously Presented) A pharmaceutical combination comprising at least:
  - a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and
  - a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaine of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with  $n$  an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof with the proviso that said second compound is different from the first compound,  
in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and  
in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.
2. (Previously Presented) The combination of claim 1, which comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 85 mg.
3. (Previously Presented) The combination of claim 1, which comprises an amount of a compound selected from the group consisting of acetylsalicylic acid, pharmaceutical derivative thereof and mixtures thereof corresponding to 3 to 80 mg calculated as acetylsalicylic acid.
4. (Previously Presented) The combination of claim 1, in which the amount of second compound is at least comprised between 5 and 100 times the amount calculated as acetylsalicylic acid weight of said first compound.
5. (Previously Presented) The combination of claim 1 as an unitary dose, in which the amount of second compound is 60 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

6. (Previously Presented) The combination of claim 1, which is prepared at least from a mixture in which at least 50% by weight of the first compound and at least 50% of the second compound are in soluble form.

7. (Previously Presented) The combination of claim 1, which is prepared at least from a mixture in which at least 90% by weight of the first compound and at least 90% of the second compound are in soluble form.

8. (Previously Presented) The combination of claim 1, which is prepared at least from a mixture in which the first compound and the second compound are substantially completely in soluble form.

9. (Previously Presented) The combination of claim 1, which the second compound is at least in a controlled release form.

10. (Previously Presented) The combination of claim 1, which the first compound is at least partly in an immediate release form.

11. (Previously Presented) The combination of claim 1, which comprises dry particles prepared by drying a mixture in which the first compound and the second compound are partly in a soluble form.

12. (Previously Presented) The combination of claim 1, in which the first compound and the second compound are combined in the form selected from the group consisting of a matrix, a gel, an hydrogel, a wax and a porous carrier, a bilayered tablet and combination thereof.

13. (Previously Presented) The combination of claim 1, which further comprises at least one compound reacting in presence of water so as to prepare substantially immediately a solution or suspension of first compound and second compound.

14. (Withdrawn) The combination of claim 1 in which the second compound comprises at least glycine betaine monohydrate.

15. (Previously Presented) The combination of claim 1 in which the second compound comprises at least glycine betaine anhydrous.

16. (Previously Presented) Pharmaceutical unit dosage form comprising at least a pharmaceutical combination containing at least:

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and

- a second compound selected from the group consisting of lipidic betaines, betaines lipid, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, or a pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound, in which the combination is prepared from a mixture in which the first compound and the second compound are partly in a soluble form.

17. (Previously Presented) The pharmaceutical form according to claim 16, which comprises less than 100 mg of said first compound expressed as acetylsalicylic acid.

18. (Previously Presented) The pharmaceutical form according to claim 16, in which the amount of second compound is at least 5 times the amount by weight of said first compound expressed as acetylsalicylic acid.

19. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is prepared from a mixture in which at least 50% by weight of the first compound and at least 50% of the second compound are in soluble form.

20. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is prepared from a mixture in which at least 90% by weight of the first compound and at least 90% of the second compound are in soluble form.

21. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is prepared from a mixture in which the first compound and the second compound are substantially completely in soluble form.

22. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is in the form of dry particles prepared by drying a mixture in which the first compound and the second compound are partly in a soluble form.

23. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is in the form selected from the group consisting of a matrix, a gel, an hydrogel, a wax and a porous carrier and combinations thereof.

24. (Previously Presented) The pharmaceutical form of claim 16, which is at least a controlled release formulation for the second compound.

25. (Previously Presented) The pharmaceutical form of claim 16, which is at least an immediate release formulation for the first compound.

26. (Previously Presented) The pharmaceutical form of claim 16, which further comprises at least one compound reacting in presence of water so as to prepare substantially immediately a solution or suspension of first compound and second compound.

27. (Previously Presented) The pharmaceutical form of claim 16, in which second compound is selected from the group consisting of glycine betaine or a pharmaceutical salt thereof.

28. (Withdrawn) A kit for a daily administration, said kit comprising at least:

- a first oral formulation comprising a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and
- a second oral formulation comprising a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, or a pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound

in which the first oral formulation comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound in the second oral formulation is at least five times the amount, calculated as acetylsalicylic acid, of said first compound.

29. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 85 mg.

30. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of a compound selected among the group consisting of acetylsalicylic acid, pharmaceutical derivative thereof and mixtures thereof corresponding to 3 to 80 mg calculated as acetylsalicylic acid.

31. (Cancelled)

32. (Withdrawn) The kit of claim 28, in which the second oral formulation comprises an amount of second compound corresponding to 10 times to 100 times by weight, calculated as acetylsalicylic acid, of said first compound.

33. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of a second compound selected from the group consisting of betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound.

34. (Withdrawn) The kit of claim 28, in which the first oral formulation is prepared at least from a mixture in which at least 50% by weight of the first compound and at least 50% of the second compound are in soluble form.

35. (Withdrawn) The kit of claim 28, in which the first oral formulation is prepared at least from a mixture in which at least 90% by weight of the first compound and at least 90% of the second compound are in soluble form.

36. (Withdrawn) The kit of claim 28, in which the first oral formulation is prepared at least from a mixture in which the first compound and the second compound are substantially completely in soluble form.

37. (Withdrawn) The kit of claim 28, n in which the second oral compound is at least in a controlled release form.

38. (Withdrawn) The kit of claim 28, in which the first oral compound is at least in an immediate release form.

39. (Withdrawn) The kit of claim 28, in which the second oral formulation is selected among the group consisting of glycine betaine and its pharmaceutically acceptable salts.

40. (Withdrawn) The use of

- a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical combination for treating or preventing blood flow disturbances, said combination comprising at least the first compound and the second compound,

in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

41. (Withdrawn) The use of

- a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical combination for treating or preventing cancer, said combination comprising at least the first compound and the second compound,

in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

42. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and

- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical combination for treating or preventing diabetes, said combination comprising at least the first compound and the second compound,

in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

43. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and

- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical combination for treating or preventing gut, said combination comprising at least the first compound and the second compound, in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

44. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_2)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical combination for treating or preventing inflammation, said combination comprising at least the first compound and the second compound, in which said combination comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

45. (Withdrawn) Process of treatment of a patient in need for treating, preventing, reducing thrombosis troubles for a patient, by administering to said patient less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and in which a therapeutic effective amount of glycine betaine is further administered to said patient, said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

46. (Withdrawn) Process of treatment of a patient in need for treating, preventing, reducing inflammation troubles in a patient, by administering to said patient less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and  
in which a therapeutic effective amount of glycine betaine is further administered to said patient, said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

47. (Withdrawn) Process of treatment of a patient in need for treating, preventing, reducing inflammation troubles in a patient, by administering to said patient less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and  
in which a therapeutic effective amount of glycine betaine is further administered to said patient, said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

48. (Withdrawn) Process of treatment of a patient in need for treating, preventing, reducing inflammation troubles in a patient, by administering to said patient less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and  
in which a therapeutic effective amount of glycine betaine is further administered to said patient, said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

49. (Withdrawn) Process of treatment of a patient in need for treating, preventing, reducing gut troubles in a patient, by administering to said patient less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and

in which a therapeutic effective amount of glycine betaine is further administered to said patient, said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

50. (Withdrawn) A pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer in an amount at least five times the amount of aspirin.

51. (Withdrawn) The pharmaceutical composition as defined in claim 50, wherein the layer containing the betaine also includes one or more buffering agents.

52. (Withdrawn) The pharmaceutical composition as defined in claim 50, wherein the tablet includes a core and a coating layer surrounding said core and wherein one of the betaine and aspirin is present in the core and the other is present in a coating layer surrounding the core.

53. (Withdrawn) The pharmaceutical composition as defined in claim 50, wherein the tablet includes a core and a coating layer surrounding said core and wherein a mixture of the betaine and aspirin is present in the core and one of the betaine and aspirin is present in the coating layer surrounding the core.

54. (Withdrawn) The pharmaceutical composition as defined in claim 52, wherein the aspirin is present in the core and the betaine is present in the coating layer.

55. (Withdrawn) The pharmaceutical composition as defined in claim 52, wherein the aspirin is present in the core and the betaine present in the coating layer is in a controlled release form.

56. (Withdrawn) The pharmaceutical composition as defined in 52, wherin the betaine is present in the core in a controlled release form and the aspirin is present in the coating layer.

57. (Withdrawn) The pharmaceutical composition as defined in claim 53 wherin the coating layer also includes at least one buffering agent.

58. (Withdrawn) The pharmaceutical composition as defined in claim 54 wherin the coating layer also includes at least one buffering agent and at least one protecting film.

59. (Withdrawn) The pharmaceutical composition as defined in claim 50 wherein the betaine is selected from the group consisting of betaines of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof.

60. (Withdrawn) The pharmaceutical composition as defined in claim 50 further including an outer protective coating or finishing layer surrounding said tablet.

61. (Withdrawn) The pharmaceutical composition as defined in claim 50 wherein the aspirin is in the form of enteric coated aspirin granules.

62. (Withdrawn) The pharmaceutical composition as defined in claim 50 in the form of a bilayered tablet which comprises a first layer comprising aspirin granules and at least one excipient, and a second layer comprising a betaine and at least one buffering compound and at least one excipient.

63. (Withdrawn) The pharmaceutical composition as defined in claim 60, wherein the first layer comprises aspirin granules and at least one bulking agent, and the second layer comprises a betaine.

64. (Withdrawn) The pharmaceutical composition of claim 50 further including an outer protective coating surrounding said bilayered tablet.

65. (Withdrawn) The pharmaceutical composition of claim 50 further including an antithrombotic agent.

66. (Withdrawn) The pharmaceutical composition of claim 50 further including an anti cancerous agent.

67. (Withdrawn) The pharmaceutical composition of claim 50 further including an anti inflammatory agent.

68. (Withdrawn) The pharmaceutical composition of claim 50 further including an antibiotic agent.

69. (Withdrawn) The pharmaceutical composition of claim 50 further including an anti diabetic agent.

70. (Withdrawn) The pharmaceutical composition of claim 50 further including an antioxidant agent.

71. (Withdrawn) A method for treating a patient suffering from atherosclerosis, which comprises administering to the patient in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer in an amount at least five times the amount of aspirin.

72. (Withdrawn) The method of claim 71, wherein the betaine employed is selected from the group consisting of anhydrous betaine, betaine monohydrate salt, lipidic betaine and betaine lipids.

73. (Withdrawn) A pharmaceutical composition comprising betaine and aspirin in a formulation to reduce aspirin side effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

74. (Withdrawn) A pharmaceutical composition comprising betaine and aspirin in a formulation to increase aspirin therapeutic effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

75. (Previously Presented) The combination of claim 1, which comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 75 mg.

76. (Previously Presented) The combination of claim 1, which comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 60 mg.

77. (Previously Presented) The combination of claim 1, which comprises an amount of a compound selected from the group consisting of acetylsalicylic acid, pharmaceutical derivative thereof and mixtures thereof corresponding to advantageously from 5 to 75 mg calculated as acetylsalicylic acid.

78. (Previously Presented) The combination of claim 1, which comprises an amount of a compound selected from the group consisting of acetylsalicylic acid, pharmaceutical derivative thereof and mixtures thereof corresponding to advantageously from 10 to 75 mg calculated as acetylsalicylic acid.

79. (Previously Presented) The combination of claim 1, in which the amount of second compound is at least comprised between 5 and 25 times the amount calculated as acetylsalicylic acid weight of said first compound.

80. (Previously Presented) The combination of claim 1, which comprises dry micro particles prepared by drying a mixture in which the first compound and the second compound are partly in a soluble form.

81. (Previously Presented) The pharmaceutical form of claim 16, in which the combination is in the form of dry micro particles prepared by drying a mixture in which the first compound and the second compound are partly in a soluble form.

82. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 75 mg.

83. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of said first compound, calculated as acetylsalicylic acid, of less than 60 mg.

84. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of a compound selected among the group consisting of acetylsalicylic acid, pharmaceutical derivative therof and mixtures thereof from 5 to 75 mg, calculated as acetylsalicylic acid.

85. (Withdrawn) The kit of claim 28, in which the first oral formulation comprises an amount of a compound selected among the group consisting of acetylsalicylic acid, pharmaceutical derivative thereof and mixtures thereof from 10 to 75 mg, calculated as acetylsalicylic acid.

## 86. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical unit dosage form for treating or preventing blood flow disturbances, said unit dosage form comprising at least a first compound, and a second compound,

in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

## 87. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound,

for the preparation of a pharmaceutical unit dosage form for treating or preventing cancer, said unit dosage form comprising at least a first compound and a second compound,

in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and

in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

88. (Withdrawn) The use of

- a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
- a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures therof, with the proviso that said second compound is different from the first compound,  
for the preparation of a pharmaceutical unit dosage form for treating or preventing diabetes, said unit dosage form comprising at least: a first compound and a second compound,  
in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and  
in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

89. (Withdrawn) The pharmaceutical composition of claim 60, wherein the first layer comprises aspirin granules and at least one bulking agent and optionally a lubricant, and the second layer comprises a betaine and at least one buffering compound selected from the group consisting of calcium carbonate, magnesium oxide, magnesium carbonate and mixtures thereof.

90. (Withdrawn) A method for reducing risk of an event selected from the group consisting of cardiovascular events, coronary artery troubles and cerebro-vascular troubles, which comprises administering to the patient at risk of such an event a therapeutically effective amount of a pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a

first layer, and the betaine being present in a second layer in an amount at least five times the amount of aspirin.

91. (Withdrawn) The method of claim 90, wherein the betaine employed is selected from the group consisting of anhydrous betaine, betaine monohydrate salt, lipidic betaine and betaine lipids.